2009.07.16 Weekly Broadcast Email
The following updates were made to the website for the week of July 13, 2009.
97405: (Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms on Men with Prostate Cancer)
Amendment 7 has been added to the website. This amendment includes CTSU information in the protocol, consent form, and appendices D and N.
Featured Study: Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients
Have you considered opening 91105 at your site? Has your site accrued patients to this study recently? You might be interested to know…
Several recent protocol changes have been made to study 91105, Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients. These changes were made to facilitate and simplify enrollment which include:
-Adding a $40 gift for participating
-Simplifying and reducing medication exclusions
Visit the recently updated 91105 webpage to view:
• Letter from the PI, Dr. Steve Rapp
• Brochure outlining recent changes
• Training video
97106 (Randomized Study to Determine whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors) only has 13 minority accrual slots open for patient accruals. We would like to see this study close by the end of the summer, so if you have patients that may be eligible for this study, please try and get them registered by then.